Agios to Participate in March Investor Conferences
March 02, 2023 08:26 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day
February 28, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® (mitapivat) in Sickle Cell Disease – – On Track to Complete Enrollment in Phase 3 ENERGIZE and ENERGIZE-T Studies of PYRUKYND® in...
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
February 02, 2023 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
January 08, 2023 20:00 ET
|
Agios Pharmaceuticals, Inc.
– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – –...
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
January 03, 2023 17:57 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
December 21, 2022 08:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
December 11, 2022 19:00 ET
|
Agios Pharmaceuticals, Inc.
– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transfusion Burden and Patient-reported Outcomes,...
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
December 10, 2022 18:30 ET
|
Agios Pharmaceuticals, Inc.
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively – – Agios to...
Agios Appoints Tsveta Milanova as Chief Commercial Officer
December 06, 2022 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...